RxDoctor Payments Data

Hannah Goldberg, MD

Internal Medicine · Reisterstown, MDNPI 1245771443

Payments from drug & device makers

$2,931in general payments, 2019–2025

Across 159 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$508
  • AbbVie$438
  • Pfizer$408
  • Lilly USA, LLC$260
  • AstraZeneca$229
  • Amgen$206
  • plus $883 from 19 others

What the payments were for

  • Food & beverage$2,931100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,931 in reported general payments places this provider in the 85th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$214,957
Medicare patients
374
Services billed
2,503

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$94,642
EliquisApixaban74$78,843
MounjaroTirzepatide47$66,578
JardianceEmpagliflozin38$43,819
TrulicityDulaglutide21$31,248
XareltoRivaroxaban11$17,544
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$15,222
JanuviaSitagliptin Phosphate16$13,380
FarxigaDapagliflozin Propanediol17$12,677
TradjentaLinagliptin15$10,642
Tresiba Flextouch U-100Insulin Degludec16$10,105
Atorvastatin Calcium423$6,091
Spiriva RespimatTiotropium Bromide11$5,575
SuboxoneBuprenorphine Hcl/Naloxone Hcl11$5,511
Rosuvastatin Calcium196$3,488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$260$97,82568 claims
Novo NordiskOzempic$508$94,64243 claims
PfizerEliquis$408$78,84374 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$70$60,03564 claims
Johnson & JohnsonXarelto$24$17,54411 claims
GSKTrelegy Ellipta$73$15,22212 claims
AstraZenecaFarxiga$229$12,67717 claims
AbbVieSynthroid$438$2,77343 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Reisterstown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →